Lexaria Bioscience Corp. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Marketable Securities

Marketable Securities

12 Months Ended

Aug. 31, 2019

21.	Marketable Securities

	The components of Marketable Securities were as follows:

	Cost Basis $		Unrealized Gains $		Unrealized Losses $			Total $
August 31, 2018
Common Stock		25,000		-		(14,849	)
Total		25,000		-		(14,849	)		10,151
August 31, 2019
Common Stock		81,250		9,335		(12,124	)
Total		81,250		9,335		(26,973	)		63,612

Unrealized losses from common stock are due to market price movements. Management does not believe any remaining unrealized losses represent other-than-temporary impairments based on our evaluation of available evidence.